Merck Earnings Hurt by Arthritis Drug Knockoffs

Low-cost knockoffs of the arthritis treatment Remicade in Europe hurt Merck & Co.’s second-quarter sales and earnings, a harbinger of the pressure facing sellers of other costly biotechnology drugs in the coming years.

What feeling does this article give you?
Joy
Disgust
Fear
Anger
Sadness

#hashtags to follow:

Remicade [+]    Europe [+]    Merck [+]   

More #news: